Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is the most common cause of dementia and the 6th leading cause of death. Although research has revealed significant information about AD, much is yet to be discovered about the precise biological changes that cause AD and how the disease could be prevented, slowed, or stopped. Accumulating evidence suggests the involvement of the non-receptor proline-rich tyrosine kinase 2 (Pyk2) in AD, but the downstream signaling events triggered by this protein and their implications on the pathology of the disease were unclear until recently. A recent paper by Giralt et al. used genetically depleted and overexpression mouse models to elucidate the role of Pyk2 in AD. Here, we discuss the findings presented in this paper in light of previous information and hypotheses, and suggest interpretations and explanations for this surprising and unexpected phenotype.
| Original language | English |
|---|---|
| Pages (from-to) | 313-317 |
| Number of pages | 5 |
| Journal | Experimental Neurology |
| Volume | 311 |
| DOIs |
|
| State | Published - Jan 2019 |
Bibliographical note
Publisher Copyright:© 2018 Elsevier Inc.
Funding
We are grateful to Kolluru Devi Dutt Srikanth for critical reading of the manuscript. Research in the Gil-Henn laboratory is supported by the Israel Cancer Association and Estee Lauder Companies (grant number 20180089 ), the Israel Science Foundation (grant number 1462/17 ), and the Israel Cancer Research Fund (grant number 17-902-AG ).
| Funders | Funder number |
|---|---|
| Estee Lauder Companies | 20180089 |
| Israel Cancer Research Fund | 17-902-AG |
| Israel Cancer Association | |
| Israel Science Foundation | 1462/17 |
Fingerprint
Dive into the research topics of 'Commentary on Giralt et al. PTK2B/Pyk2 overexpression improves a mouse model of Alzheimer's disease'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver